Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of DYX116 versus placebo and semaglutide in adults with type 2 diabetes mellitus
CTR20261893Phase 2Active
- Sponsor
- Jiangsu Deyuan Pharmaceutical
- Start
- May 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of DYX116 in type 2 diabetes mellitus (T2DM), sponsored by Jiangsu Deyuan Pharmaceutical. Started May 2026; status: active.
02
Drugs
DYX116
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20261893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261893.